Noble Capital Markets analysts have maintained their ‘Market Perform’ rating on MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF) following the company’s announcement of a proposed equity financing, citing continued commercial progress alongside near-term execution considerations.
MustGrow said it plans to raise up to $2 million through a non-brokered private placement of up to 4 million units priced at $0.50 per unit. Each unit will include one common share and one common share purchase warrant, with each whole warrant exercisable for 60 months at an exercise price of $0.70 per share.
Charbone Hydrogen Corporation (TSX-V:CH, OTCQB:CHHYF), a North American producer and distributor of ultra-high purity (UHP) hydrogen and industrial gases, announced the closing of a non-brokered private placement, raising gross proceeds of $3.1 million.
The company issued 23,614,286 units at $0.13125 per unit. Each unit consists of one common share and one common share purchase warrant. The warrants allow holders to purchase an additional share at $0.18 over 24 months, with an acceleration clause if the company’s share price reaches $0.30 for 10 consecutive trading days on the TSX Venture Exchange.
NextSource Materials Inc. (TSX:NEXT, OTCQB:NSRCF) announced that it has finalized multiple term sheets with strategic investors to fund Phase 1 of its proposed Battery Anode Facility (BAF) in the Industrial City of Abu Dhabi, United Arab Emirates.
The company said the term sheets mark progress in its strategic financing process and support its path toward a final investment decision.
EDM Resources Inc (TSX-V:EDM, OTC:SWNLF) has reflected on its key accomplishments in 2025 and outlined its planned operational, permitting, and commercial milestones for 2026 as the company advances the Scotia Mine near Halifax toward a production decision.
In 2025, the company said it completed all major planned milestones while continuing permitting and technical work related to a potential restart of operations at the Scotia Mine.
Medicus Pharma (NASDAQ:MDCX) announced that it will present new Phase 1 clinical data on its long-acting gonadotropin-releasing hormone (GnRH) antagonist Teverelix at the American Association of Clinical Endocrinology (AACE) Annual Meeting in April 2026.
The company said its abstract, titled “Evaluation of Teverelix, a Long-Acting GnRH Antagonist: Pharmacokinetics, Pharmacodynamics, Bone Turnover and Safety in Two Phase 1 Studies in Healthy Female Volunteers,” has been accepted for e-Poster presentation at the meeting, which will be held April 22 to 24 in Las Vegas.
Digi Power X Inc (NASDAQ:DGXX, TSX-V:DGX) announced that it has entered into a definitive agreement to acquire approximately $20 million of next-generation NVIDIA B300 graphics processing units from Super Micro Computer, as the company expands its AI-focused digital infrastructure operations.
The company said the GPU systems will be deployed within its Tier III AI data center infrastructure and offered through its NeoCloudz platform, a GPU-as-a-Service product. Initial customer availability for NeoCloudz is targeted for March 2026.
C3 Metals Inc (TSX-V:CCCM, OTC:CUAUF) announces that it has restarted full exploration activities in Jamaica after restoring project infrastructure damaged by Hurricane Melissa, which made landfall on the island on October 28, 2025.
The company said restoration work allowed exploration programs to resume across its Jamaican projects while community assistance efforts were carried out in affected areas.
Shares in Futura Medical PLC (AIM:FUM, OTC:FAMDF) rose 11% to 1.45p on Monday after the company unveiled positive early-stage trial results for a new gel aimed at treating sexual dysfunction in women, a potential first in the over-the-counter market.
The AIM-listed group, best known for its erectile dysfunction product Eroxon, said its WSD4000 gel had shown “highly statistically significant” improvements in sexual function during a small feasibility study.
Corero Network Security PLC (AIM:CNS, OTCQB:DDOSF) shares climbed higher on Monday, after the firm told investors it expects revenue for FY 2025 to reach the upper end of guidance at $25.5 million.
The company also said it expects earnings (EBITDA) to exceed $1.3 million, driven by strong sales momentum in the second half of the year.
Union Jack Oil PLC (AIM:UJO, OTCQB:UJOGF) announced it has appointed Dr Zac Phillips and John Americanos as non-executive directors with immediate effect. Meanwhile, Craig Howie departed his rola as director.
Zac Phillips joins as an independent non-executive director and will also take on the role of senior independent director.
Renalytix PLC (AIM:RENX, OTC:RNLXY), the diagnostics company behind the kidney disease risk test kidneyintelX.dkd, has signed up three more US healthcare providers, as it looks to grow uptake of its FDA-approved testing platform.
The London and New York-based firm said it had completed clinical integrations with practices in New York, Florida and Tennessee in the final quarter of last year.
CelLBxHealth PLC (AIM:CLBX, OTCQB:ANPCF) has confirmed board appointments signed off at a board meeting last month, with its chief executive and three non-executive directors formally taking up their roles at the cancer diagnostics company.
Peter Collins takes on the role of CEO, while Klaas de Boer, Kim Oreskovic and Benjamin Hart join the board as non-executive directors.
Futura Medical PLC (AIM:FUM, OTC:FAMDF), the company behind the over-the-counter erectile dysfunction gel Eroxon, has announced encouraging early trial results for a new product aimed at treating sexual dysfunction in women.
The study, though small, showed what Futura called “highly statistically significant” improvements in sexual function among women using its WSD4000 gel, a topical treatment still in development.
Firebird Metals Ltd (ASX:FRB, OTC:FRBMF) has completed installation and commissioning of proprietary cathode active material (CAM) equipment at its wholly owned China pilot plant, clearing the way for initial production of lithium–manganese-rich (LMR) cathode materials.
The milestone positions Firebird to begin initial LMR CAM production in February 2026, with customer sampling scheduled for the second half of the year to support technical engagement, evaluation and qualification programs.